17. references-chapter-7.pdf
Transcript of 17. references-chapter-7.pdf
I
CHAPTER-7
REFRENCES
1. Abbas, A.K., K.M. Murphy and A. Sher (1996) Functional diversity of helper T
lymphocytes. Nature 383: 787-793.
2. Abda, A.M., J. Henry and F. Jday (2011) Boundary data completion: the method of
boundary value problem factorization. Inverse Problems 27(5):055014
3. Afrin, F., and N. Ali (1997) Adjuvanticity and protective immunity elicited by
Leishmania donovani antigen encapsulated in positively charged liposomes. Infect
Immun 65:2371-2377.
4. Aggarwal, G., E.A. Worthey, P. D. McDonagh and P. J. Myler (2003) Importing
statistical measures into Artemis enhances gene identification in the Leishmania
genome project. BMC Bioinformatics 4: 23.
5. Alavar, J., C.Canavate, B.Guitierrez-Solar, M. Jimenez, F. Laguna, R. Lopez-Veler, R.
Molina and J. Moreno (1997) Leishmania and human immunodeficiency virus co-
infection: the first 10 years. Clin Microbiol Rev 10:298-319.
6. Alexander, J., A.R. Satoskar and D.G. Russell (1999) Leishmania species: models of
intracellular parasitism. J Cell Sci 12 ( 18): 2993-3002.
7. Alexander, J., and D.G. Russell (1992) The interaction of Leishmania species with
macrophages. Adv Parasitol 31:175-254.
8. Alexander, J., K.C. Carter, N. Al-Fasi, A. Satoskar and F. Brombacher (2000).
Endogenous IL-4 is necessary for effective drug therapy against visceral
leishmaniasis. Eur J Immunol 30: 293-243.
9. Al-Jawabreh, A., L.F. Schnur, A. Nasereddin , J.M. Schwenkenbecher, Z. Abdeen, F.
Barghuthy, H. Khanfar, W. Presberet and G. Schonian (2004) The recent
emergence of Leishmania tropica in Jericho (A'riha) and its environs, a classical
focus of L. major. Trop Med Int Health 9(7): 812-816.
10. Al-Nahhas, S.A., and R.M. Kaldas (2013) Characterization of Leishmania species
isolated from cutaneous human samples from central region of Syria by RFLP
analysis. Hindawi publishing corporation ISRN Parasitology 308726.
11. Alvar ,J., P. Aparicio, A. Aseffa, M. Den Boer, C. Cañavate, J.P. Dedet, L. Gradoni, R
. ter Horst, R. López-Vélez and J. Moreno (2008) The re-The re-lationship between
leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21: 334-359.
II
12. Alvar, J., S. Croft and P. Olliaro (2006) Chemotherapy in the treatment and control of
leishmaniasis. Adv Parasitol 61: 223-274.
13. Anam, K., F. Afrin, D. Banerjee, N. Pramanik, S.K. Guha, R.P. Goswami, S.K Saha
and N. Ali (1999a) Differential decline in Leishmania membrane antigen-specific
immunoglobulin G (IgG), IgM, IgE, and IgG subclass antibodies in Indian kala-
azar patients after chemotherapy. Infect Immun 67: 6663–6669.
14. Anam, K., F. Afrin, D. Banerjee, N. Pramanik, S. K.Guha, R. P. Goswami, P. N.Gupta,
S. K. Saha, and N. Ali (1999b) Immunoglobulin subclass distribution and
diagnostic value of Leishmania donovani antigen-specific immunoglobulin G3 in
Indian kala-azar patients. Clin Diagn Lab Immunol 6:231–23
15. Anderson, C. F., M. Oukka, V.J. Kuchroo and D. Sacks, (2007) CD4 (+) CD25 (-)
Foxp3 (-) Th1 cells are the source of IL-10- mediated immune suppression in
chronic cutaneous leishmaniasis. J Exp Med 204: 285-297.
16. Anderson, C. F., S. Mendez and D. L. Sacks (2005) Non healing infection despite Th1
polarization produced by a strain of Leishmania major in C57BL/6 mice. J Immunol
174: 2934-2941.
17. Ansari, N. A., V. Ramesh and P. Salotra (2006) Interferon (IFN)-γ, tumor necrosis
factor-α, interleukin-6, and IFN- γ receptor 1 are the major immunological
determinants associated with post-kala-azar dermal leishmaniasis. J Infect Dis
194:958–65.
18. Ansari, N.A., R. Kumar, S. Gautam, S. Nylen, O.P. Singh, S. Sundar and D. Sacks
(2011) IL-27andIL-21 are associated with Tcell IL-10 responses in human visceral
leishmaniasis. J Immunol 186: 3977-3985.
19. Ansari, N.A., S.Saluja and P. Salotra (2006) Elevated levels of interferon
gamma,interleukin-10, and interleukin-6 during active disease in Indian kala azar.
Clin Immunol 119:339-45.
20. Antonelli, L. R., W. O. Dutra, R. P. Almeida, O. Bacellar, E. M. Carvalho and K. J.
Gollob, (2005) Activated inflammatory T cells correlate with lesion size in human
cutaneous leishmaniasis. Immunol Lett 101: 226-230.
21. Arnoldi, J., and H. Moll (1998) Langerhans Cell Migration in Murine Cutaneous
Leishmaniasis: Regulation by Tumor Necrosis Factor Interleukin-l/3, and
Macrophage Inflammatory Protein-1α. Developmental Immunology 6:3-11.
III
22. Assreuy, J., F.Q. Cunha, M. Epperlein, A. Noronha-Dutra and C.A. O’Donnell et al.,
(1994) Production of nitric oxide and superoxide by activated macrophages and
killing of Leishmania major. Eur J Immunol 24: 672–676.
23. Atta, A.M., A. D. Oliveira, J. Correa, M. L. Atta, R. P. Almeida and E. M. Carvalho
(1998) Anti-leishmanial IgE antibodies: a marker of active disease in visceral
leishmaniasis. Am J Trop Med Hyg 59: 426-430.
24. Baccala, R., K. Hoebe, D. H. Kono, B. Beutler and A. N. Theofilopoulos (2007) TLR-
dependent and TLR-independent pathways of type I interferon induction in
systemic autoimmunity. Nat Med 13: 543–551.
25. Bamford, R.N., A.P. Battiata and J.D.Burton, H. Sharma and T. A. Waldmann (1996)
Interleukin (IL)-15/IL-T production by the adult T-cell leukemia cell line HuT-102
is associated with a human T-cell lymphotrophic virus type I R region/IL-15 fusion
message that lacks many upstream AUGs that normally attenuate IL-15 mRNA
translation. Proc Natl Acad Sci USA. 93:2897-902.
26. Beadling, C., K.W. Johnson and K.A.(1993) Isolation of interlukin2-induced immediate
early genes. Proc Natl Acad Sci USA 90(7): 2719-2723.
27. Beer, P., A.E.C. de Harit, L.L.Deng, S.J. Semião-Santos, B. Chantal and M. Grootheest
(1991) A killing disease epidemic among displaced sudanese population identified
as visceral leishmaniasis. Am J Trop Med Hyg 44: 283-289.
28. Behin, R., and L. Jacques (1984) Immune response to Leishmania. Crit Rev Trop Med 2: 141-
188.
29. Belkaid, Y., C.A. Piccirillo, S. Mendez, E.M. Shevach and D.L.Sacks (2002)
CD4+CD25+ regulatory T cells control Leishmania major persistence and
immunity. Nature 420(6915):502-507.
30. Bensoussan ,E., A. Nasereddin, F. Jonas, L. F.Schnur and C.L. Jaffe (2006) Comparison
of PCR assays for diagnosis of cutaneous leishmaniasis. J Clin Microbiol 44: 1435-
1439.
31. Berman, J.D. (1997) Human leishmaniasis: Clinical, diagnostic, and chemotherapeutic
developments in the last 10 years. Clin Inf Dis 24:684-703.
32. Bhattacharjee, S., G. Gupta, P. Bhattacharya, A. Mukherjee, S.B. Mujumdar, A. Pal and
S. Majumdar (2009) Quassin alters the immunological patterns of murine
macrophages through generation of nitric oxide to exert antileishmanial activity. J
Antimicrob Chemother 63: 317-324.
IV
33. Bogdan, C., H. Moll, W. Solbach and M. Rollinghoff (1990) Tumour necrosis factor-
alpha in combination with interferon-gamma, but not with interleukin 4 activates
murine macrophages for elimination of Leishmania major amastigotes. Eur J
Immunol 20: 1131-1135.
34. Bray, R. S. (1976) Immunodiagnosis of leishmaniasis. In S. Cohen and E. H. Sadun
(ed.), Immunology of parasitic infections. Blackwell Scientific Publications,
Oxford, England 65-76.
35. Brittingham , A ., C.J. Morrison, W.R. McMaster, B.S. McGwire, K.P. Chang and
D.M. Mosser (1995) Role of the Leishmania surface protease gp63 in
complement fixation, cell adhesion, and resistance to complement-mediated lysis.
The Journal of Immunology .155: 3102-11.
36. Brown, M.A., and J. Hural (1997) Functions of IL-4 and control of its expression. Crit
Rev Immuno 17 (1997): 1-32.
37. Buxbaum, L.U., and P. Scott (2005) Interleukin 10 and Fcγ Receptor Deficient Mice
Resolve Leishmania Mexicana Lesions. Infec Immunity 73(4): 2101-2108.
38. Caldas, A., C. Favali, D. Aquino, V. Vinhas, J. van Weyenbergh, C. Brodskyn, J. Costa,
M. Barral-Netto, and A. Barral (2005) Balance of Il-10 and Interferon-Gamma
Plasma Levels in Human Visceral Leishmaniasis: Implications in the Pathogenesis.
BMC Infect Dis 5:113.
39. Carvalho, E. M., O. Bacellar, C. Brownell, T. Regis, R. L. Coffman and S. G. Reed
(1994) Restoration of IFN-gamma production and lymphocyte proliferation in
visceral leishmaniasis. J Immunol 152: 5949-5956.
40. Carvalho, E.M., O.Bacelar and C.E. Brownell et al. (1994) Restoration of IFN-gamma
production and lymphocyte proliferation in visceral leishmaniasis. J Immunol
152:5949-5956.
41. Carvalho, E.M., R. Badaro, S. G. Reed, T. C. Jones, and W. D. Johnson (1985) Absence
of gamma-interferon and interleukin 2 production during active visceral
leishmaniasis. J. Clin. Investig 76:2066–2069.
42. Choudhry, A., P.Y. Guru, R.P. Saxena, A. Tandon and K.C.Saxena (1990) Enzyme-
Linked immunosorbent assay in the diagnosis of kala-azar in Bhadohi (Varanasi),
India. Trans R Soc Trop Med Hyg 84: 363-366.
43. Chouihi, E., F. Amri, N. Bouslimi, E. Siala and K. Selmi (2009) Cultures on NNN
medium for the diagnosis of leishmaniasis. Pathol Bio 57: 219-224.
V
44. Clements, M. F., K. Gidwani, R. Kumar, J. Hostomska, D. S. Dinesh, V.Kumar, P.Das,
I. Muller, G. Hamilton, V. Volfova, M. Boelaert, M. Das, S. Rijal, A. Picado,
P.Volf, S. Sundar, C. R. Davies and M. E. Rogers (2010) Measurement of recent
exposure to Phlebotomus argentipes, the vector of Indian visceral leishmaniasis, by
using human antibody responses to sand fly saliva. Am J Trop Med Hyg 82:801-
807.
45. Convit, J., M. Ulrich, C.T. Fernández, F.J.Tapia, G. Cáceres-Dittmar, M. Castés and
A.J. Rondón (1993) The clinical and immunological spectrum of American
cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 87: 444- 448.
46. Costa, A.S.A., G.C. Costa, D. M. C. de Aquino, V. R. R. de Mendonça, A. Barral, M.
Barral-Netto, A.de Jesus Mendes Caldas (2012) Cytokines and visceral
leishmaniasis: a comparison of plasma cytokine profiles between the clinical forms
of visceral leishmaniasis. Mem Inst Oswaldo Cruz, Rio de Janeiro 107(6): 735-
739.
47. Croft, S.L., and G.H. Coombs (2003) Leishmaniasis current chemotherapy and recent
advances in search for novel drugs. Trends in Parasitology 19: 502-508
48. Croft, S.L., K. Seifert and V. Yardley (2006) Current scenario of drug development for
leishmaniasis. Indian J Med Res 123: 399-410.
49. Crowther J.R. (2001) The ELISA guide book. Methods in molecular biology 149.
50. Cruz I, J. Nieto, J. Moreno, C. Cañavate, P. Desjeux and J. Alvar (2006)
Leishmania/HIV co-infections in the second decade. Indian J Med Res 123: 357-
388.
51. Da Matta, V. L., S. Hoshino-Shimizu, R. Dietze and C. E. Corbett (2000) Detection of
specific antibody isotypes and subtypes before and after treatment of American
visceral leishmaniasis. J Clin Lab Anal 14: 5-12.
52. Dafa'alla, T.H., H.W. Ghalib, A. Abdel-Mageed and J.F. Williams (1992) The profile of
IgG and IgG subclasses on onchocerciasis patients. Clin Exp Immunol 88:258-263.
53. Davila, A.M., and H. Momen (2000) Internal-transcribed-spacer (ITS) sequences used
to explore phylogenetic relationships with in Leishmania. Ann Trop Med Parasitol
94(6): 651-654.
54. De Janeiro, R. (2009) Leishmaniasis epidemiology network South America. Manual
Molecular procedure 27-29.
VI
55. De Waal Malefyt, R., J. Abrams, B. Bennett, C.G. Figdor and J.E. De Vries (1989)
Interleukin 10(IL10) inhibits cytokine synthesis by human monocytes: an
autoregulatory role of IL-10 produced by monocytes. J Exp Med 17: 1209-1220.
56. Decuypere, S., M. Vanaerschot, K. Brunker, H. Imamura, S. Muller, B. Khanal, S.
Rijal, J. C. Dujardin and G. H. Coombs (2012) Molecular mechanisms of drug
resistance in natural Leishmania populations vary with genetic background. PLoS
Negl Trop Dis 6: e1514.
57. Defrance ,T., B. Vanbervliet, J. P. Aubry, Y.Takebe, N. Arai, A. Miyajima, T. Yokota,
F. Lee, K. Arai, J. E. de Vries and J. Banchereau (1987) B cell growth-promoting
activity of recombinant human interleukin 4. J Immunol 139:1135-1141.
58. Depinay, N., J.F. Franetich J.F. A.C. Gruner M. Mauduit, J.M. Chavatte, A. J. Lutty and
L. Renia (2011) Inhibitory effect of TNF-α on malaria pre-erythrocytic stage
development: influence of host hepatocyte/parasite combination. Plos One 6(3): e
7464.doi:10.1371/journal.pone 0017464.
59. Desjeux, P. (2004) Leishmaniasis current situation and new perspectives Comp
Immunol Microbial Infect Dis 27: 305-318.
60. Diehl, S., and M. Rincon (2002) The two faces of IL-6 on Th1/Th2 differentiation. Mol
Immunol 39: 531-536.
61. Donnelly, K.B., H.C. Lima and R.G. Titus (1998) Histologic characterization of
experimental cutaneous leishmaniasis in mice infected with Leishmania
braziliensis in the presence or absence of sand fly vector salivary gland lysate. J
Parasitol 84: 97-103
62. Downing, T., H. Imamura , S. Decuypere, T.G. Clark, G.H. Coombs, J.A.Cotton, J.D.
Hilley, S. de Doncker, I. Maes, J.C. Mottram, M.A.Quail, S. Rijal, M. Sanders, G.
Schönian, O. Stark, S. Sundar, M. Vanaerschot, C. Hertz-Fowler, J.C. Dujardin and
M. Berriman (2011) Whole genome sequencing of multiple Leishmania donovani
clinical isolates provides insights into the evolution and mechanisms of drug
resistance. Genome Res 21(12): 2143-2156.
63. Dujardin, J.C., L. Campino, C. Cañavate, J.P. Dedet, L. Gradoni, K. Soteriadou, A.
Mazeris, Y. Ozbel and M. Boelaert (2008) Spread of vector-borne diseases and
neglect of Leishmaniasis in Europe. Emerg Infect Dis 2008 14:1013-8.
64. El Amin, E.M., E.P.Wright and A. Vlug (1986) Characterization of the humoral
immune response in Sudanese leishmaniasis: specific antibody detected by class
and subclass-specific reagents. Clin Exp Immunol 64:14-9.
VII
65. El-On, J., E. Bazarsky and R. Sneir (2007) Leishmania major: In vitro and in vivo
antileishmanial activity of paromomycin ointment (Leshcutan) combined with the
immunomodulator Imiquimod. Exp Parasitol 116:156-162.
66. Engwerda, C.R., M. Ato, S. Stager, C.E. Alexander, A. C. Stanley and P.M. Kaye
(2004) Distinct roles for lymphotoxin-alpha and tumor necrosis factor in the
control of Leishmania donovani infection. Am J Pathol 165: 2123-2133.
67. Evans, K.J., and L. Kedzierski (2012) Development of Vaccines against Visceral
Leishmaniasis. Journal of Tropical Medicine doi:10.1155/2012/892817.
68. Farrell, N.P., J.Williamson and J.M. McLaren (1984). Trypanocidal and antitumor
activity of platinum metal and platinum metal drug dual function complexes.
Biochem Pharmacol 33: 961-971.
69. Felsenstein, J. (1985) Confidence limits on phylogenies: An approach using the
bootstrap. Evolution 39: 783-791.
70. Finkelman, F.D., A. Svetic, I. Gresser, C. Snapper, J. Holmes, P.P. Trotta, I.M. Katona
and W.C. Gause (1991) Regulation by interferon alpha of immunoglobulin isotype
selection and lymphokine production in mice. J Exp Med 174: 1179-1188.
71. Fiorentino, D. F., A. Zlotnik, P. Vieira, T. R. Mosmann, M. Howard, K. W. Moore, A.
O’Garra (1991) IL-10 acts on the antigen-presenting cell to inhibit cytokine
production by Th1 cells. J Immunol 146: 3444-3451.
72. Follador, I., C. Araujo, O. Bacellar, C. B. Araujo, L.P. Carvalho, R. P. Almeida and
E.M. Carvalho (2002) Epidemiologic and Immunologic Findings for the
Subclinical Form of Leishmania braziliensis Infection. Clin Infect. Dis 34(11):54-
58.
73. Fruth, U., N. Solioz and J.A. Louis (1993) Leishmania major interferes with antigen
presentation by infected macrophages. J. Immunol 150:1857-1864.
74. Ganguly, S., N.K. Das, M. Panja, S. Pal, D. Modak, M. Rahaman, S. Malik, S. K. Guha,
N. Pramanik, R. Goswami, J. N. Barbhuiya, B. Saha and M. Chatterjee (2008)
Increased Levels of Interleukin-10 and IgG3 Are Hallmarks of Indian Post–Kala-
Azar Dermal Leishmaniasis. J Infect Dis 197: 1762-1771.
75. Garraud, O., R. Perraut, G. Riveau and T.B. Nutman (2003) Class and subclass
selection in parasite-specific antibody responses. Trends Parasitol 19:300-304.
76. Gasim, S., A.M. Elhassan, E. A. Khalil, A. Ismail, A.M. Kadaru, A. Kharazmi and T.G.
Theander (1998) High levels of plasma IL-10 and expression of IL-10 by
VIII
keratinocytes during visceral leishmaniasis predict sub-sequent development of
post-kala- azar dermal leishmaniasis. Clin Exp Immunol 111: 64-69.
77. Gautam, S., R. Kumar, R. Maurya, S. Nylen, N. Ansari, M. Rai, S. Sundar and D. Sacks
(2011) IL-10 neu-tralization promotes parasite clearance in splenic aspirate cells
from patients with visceral leishmaniasis. J Infect Dis 204:1134-1137.
78. Ghalib, H.W. M. R. Piuvenzam, Y.A. Skeily, M. Sidding, F.A. Hashim, A.M. El-
Hassan, D. M. Russo, and S. G. Reed (1993) Interleukin 10 production correlates
with pathology in human Leishmania donovani infection. J Clin Invest 92(1): 324-
329.
79. Ghose, A. C., J. P. Haldar, S. C. Pal, B. P. Mishra and K. K. Mishra (1980). Serological
investigations on Indian kala-azar. Clin Exp Immunol 40:318-326.
80. Ghosh, K., G. Sharma, A. Saha, S. Kar and P.K. Das and A. Ukil (2013) Successful
therapy of visceral leishmaniasis with curdlan involves T-helper 17 cytokines. J
Infect Dis 207: 1016-1025.
81. Ghosh, M.K., A. Nandy, M. Addy, T.K. Maitra and A. C. Ghose (1995) Subpopulations
of T lymphocytes in the peripheral blood, dermal lesions and lymph nodes of post
kala-azar dermal leishmaniasis patients. Scand J Immunol 41:11–7.
82. Gidwani, K., S. Jones, R. Kumar, M. Boelaert and S. Sundar, (2011) Interferon-gamma
release assay (modified QuantiFERON) as a potential marker of infection for
Leishmania donovani, a proof of concept study. PLoS Negl Trop Dis 5:
e1042.doi:10.1371/journal. pntd.0001042
83. Goto, H., and J.A. Lindoso (2004) Immunity and immunosuppression in experimental
visceral leishmaniasis. Braz J med Boil Res 37: 615-623.
84. Goto, H., and M.G. Prianti (2009) Immunoactivation and immunopathogeny during
active visceral leishmaniasis. Rev Inst Med Trop Sao Paulo 51: 241-246.
85. Gyan, B.A., B. Goka, J.T. Cvetkovic, J.L. Kurtzhals, V. Adabayeri, H. Perlmann, A‐K.
Lefvert, B. D. Akanmori, and M. Troye‐blomberg (2004) Allelic polymorphisms in
the repeat and promoter regions of the interleukin-4gene and malaria severity in
Ghanaian children. Clinical and experimental Immunology 138: 145-150.
86. Hailu, A., P.T. Van Der, N. Berhe and P.A. Kager (2004) Elevated plasma levels of
interferon (IFN)-gamma, IFN-gamma inducing cytokines and IFN-gamma
inducible CXC chemokines in visceral leishmaniasis. Am J Trop Med Hyg 71: 561-
567.
IX
87. Haldar, A. K., P. Sen and S. Roy (2011) Use of Antimony in the Treatment of
Leishmaniasis: Current Status and Future Directions. Mol Biol Int 571242 doi:
10.4061/2011/571242.
88. Haldar, A.K., V. Yadav, E. Singhal, K.K. Bisht, A. Singh, S. Bhaumik, R. Basu, P. Sen
mail and S. Roy (2010) Leishmania donovani isolates with antimony-resistant but
not-sensitive phenotype inhibit sodium antimony gluconate-induced dendritic cell
activation. PLoS Pathog 6: e1000907. doi: 10.1371/journal.ppat.1000907.
89. Haldar, J.P., S. Ghose, K.C. Saha and A.C.Ghose (1983) Cell-mediated immune
response in Indian kala-azar and post-kala-azar dermal leishmaniasis. Infect Immun
42: 702-7.
90. Harris, E., E. Videa, E. Perez, E. Sandoval, Y. Tellez, M.L. Perez,R.Cuadra,
J.Rocha,W. Idiaquez, R.E. Alonso, M.A. Delgado, L.A. Campo, F. Acevedo, A.
Gonzalez, J.J. Amador and A. Balmaseda 2000) Clinical, Epidemiologic, and
Virologic Features of Dengue in the 1998 Epidemic in Nicaragua. Am J Trop Med
Hyg 63:5-11.
91. Hedrick, R.P., M. El-Matbouli, M.A. Adkinson and E. McConnell (1998) Whirling
disease: re-emergence among wild trout. Immunol Rev 166:365-376.
92. Heinzel, F.P., D.S. Schoenhaut, R.M. Rerko, L.E. Rosser and M.K. Gately (1993)
Recombinant Interleukin 12 cures mice infected with Leishmania major. J Exp
Med 177: 1505-1509.
93. Hermoso, T., Z. Fishelson, S. I. Becker, K. Hirschberg and C.L. Jaffe (1991)
Leishmanial Protein Kinases Phosphorylate Components of the Complement
System. The EMBO Journal. 10: 4061-4067.
94. Herwaldt, B. L. (1999) Leishmaniasis. Lancet 354:1191–1199.
95. Himmelrich, H., C. Parra-Lopez, F. Tacchini-Cottier, J. A. Louis and P. Launois (1998)
The IL-4rapidly produced in balb/C mice after infection with Leishmania major
down regulates IL-12 receptor beta 2 chain expression on CD4+ T cells resulting in
a state of unresponsiveness to IL-12. J Immunol 161:6156-6163.
96. Holaday, B.J., M.D. Sadick, Z.E. Wang, S.L. Reiner, F.P.Heinzel, T.G. Parslow and
R.M. Locksley (1991) Reconstitution of Leishmania immunity in severe combined
immunodeficient mice using Th1- and Th2-like cell lines. J Immunol 147(5):1653-
1658.
X
97. Hommel, M., W. Peters, J. Ranque, M. Quilici and G. Lanotte (1978) The micro-ELISA
technique in the serodiagnosis of visceral leishmaniasis. Ann Trop Med Parasitol
72:213-218.
98. Ishida, H., C. Matsuzaki-Moriya, T.Imami, K. Yanagisawa, Y. Nojima, K. Suzue, M.
Hirai, Y. Iwakura, A. Yoshimura, S. Hamano, C. Shimokawa and H.Hisaeda
(2010) Development of experimental cerebral malaria is independent of IL-23 and
IL-17. Biochem Biophys Res Commun 402(4):790-795.
99. Iskander, R., P.K. Das and R.C. Aalberse (1981) IgG4 antibodies in Egyptian patients
with schistosomiasis. Int Arch Allergy Appl Immunol 66: 200.
100. Jahn, A., J.M. Lelmett and H.J. Diesfeld (1986) Seroepidemiological study of kala-azar
in Beringo District, Kenya. J Trop Med Hyg 89: 91-94.
101. Jassim, A., K. Hassan and D. Catty (1987). Antibody isotypes in human
Schistosomiasis mansoni. Parasit Immunol 9:627-650.
102. Jefferis, R. (1990) Structure/function relationships of IgG subclasses. In F. Shakib (ed.),
The human IgG subclasses: molecular analysis of structure, function and
regulation. Pergamon Press, London, England 93-108.
103. Kane, M., and D.M. Mosser (2001) The role of IL-10 in promoting disease progression
in leishmaniasis. J Immunol 166:1141-1147.
104. Kar, S., G. Sharma and P.K. Das (2011) Fucoidan cures infection with both antimony
susceptible and resistant strains of Leishmania donovani through Th1 response and
macrophage-derived oxidantnts. J Antimicrob Chemother 66: 618–625.
105. Karp, C. L., S. H. El-Safi, T. A. Wynn, M. M. H. Satti, A. M. Kordofani, F. A. Hashim,
M. Hag-Ali, F. A. Neva, T. B. Nutman and D. L. Sacks (1993) In vivo cytokine
profiles in patients with kala-azar. Marked elevation of both interleukin 10 and
interferon gamma. J Clin Investig 91:1644-1648.
106. Kemp, M., T.G. Theander and A. Kharazmi (1996) The contrasting roles of CD4+ T
cells in intracellular infections in humans: leishmaniasis as an example. Immunol
Today 17: 13–16.
107. Kenney, R.T., D.L. Sacks, A.A. Gam, H.W. Murray and S. Sundar (1998) Splenic
cytokine responses in Indian kala-azar before and after treatment. J Infect Dis
177:815- 818.
108. Kima, P. E., N. H. Ruddle and D. Mcmahon-Pratt (1997) Pre-sentation via the class I
path- way by Leishmania amazonensis infected macrophages of an endogenous
leishmanial antigen to CD8+T cells. J Immunol 159: 1828-1834.
XI
109. Kubo, M. and M. Yasutaka (2012) Transcriptional regulation of the anti-inflammatory
cytokine IL-10 in acquired immune cells. Fronteirs Immune 3(275): 1-9.
110. Kurkjian, K.M., A.J. Mahmutovic and K.L. Kellar, R. Haque, C. Bern and W. E. Secor
(2006) Multiplex analysis of circulating cytokines in the sera of patients with
different clinical forms of visceral leishmaniasis. Cytometry A 69: 353-358.
111. Kurkjian, Katie M., Aida J. Mahmutovic, Kathryn L. Kellar, Rashidul Haque, Caryn
Bern, and W. Evan Secor. "Multiplex analysis of circulating cytokines in the sera
of patients with different clinical forms of visceral leishmaniasis."Cytometry Part
A 69, no. 5 (2006): 353-358.
112. Launois, P., F. Tacchini-Cottier, C. Parra-Lopez and J.A. Louis (1998) Cytokines in
parasitic diseases: the example of cutaneous leishmaniasis. Int Rev Immunol 17:
157-180.
113. Laurenti, M. D., M. Gidlund, D.M. Ura, I. L. Sinhorini, C. E.Corbett and H. Goto
(1999) The role of natural killercells in the early period of infection in murine
Cutaneous leishmaniasis. Braz J Med Biol Res 32:323-325.
114. Le Bon, A., G. Schiavoni, G. D'Agostino, I. Gresser, F. Belardelli and D.F. Tough
(2001) Type I interferons potently enhance humoral immunity and can promote
isotype switching by stimulating dendritic cells in vivo. Immunity 14: 461-470.
115. Lee, D., O. Redfern and C. Orengo (2008) Predicting protein function from sequence
and structure. Nat Rev Mol Cell Biol. 8: 995.
116. Leon, B., M. Lopez-Bravo and C. Ardavin (2007) Monocyte-derived dendritic cells
formed at the infection site control the induction of protective T helper 1 responses
against Leishmania. Immunity 26: 519-531.
117. Lima, G.M., A.L. Vallochi, U. R. Silva, E. M. Bevilacqua, M. M. Kiffer and I.A.
Abrahamsohn (1998) The role of polymorphonuclear leukocytes in the resistance
to cutaneous Leishmaniasis. Immunol Lett 64: 145-151.
118. Lopez, K.S., S. Dinges, K. Griewank, Y. Iwakura, M.C. Udey and E. von Stebut (2009)
IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice. J
Immunol 182:3039-3046.
119. Lowry, O.H., N.J. Rosenbrough, A.L. Farr and R.J. Randall (1951) Protein
measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
120. Luzza, F., T. Parrello, G. Monteleone, L. Sebkova, M. Romano, R. Zarrilli, M. Imeneo
and F. Pallone (2000) Up-regulation of IL-17 is associated with bioactive IL-8
XII
expression in Helicobacter pylori- infected human gastric mucosa. J Immunol 165:
5332-5337.
121. Lyons, S., H. Veeken and J. Long (2003) Visceral leishmaniasis and HIV inTigray,
Ethiopia. Trop Med Int Health 8(8): 733-739.
122. Malla, N., and R.C. Mahajan (2006) Pathophysiology of visceral leishmaniasis: some
recent concepts. Indian J Med Res 123(3):267-274.
123. McCartney, S., W. Vermi, S. Gilfillan, M. Cella, T.L. Murphy, R.D. Schreiber, K.M.
Murphy and M. Colonna(2009) Distinct and complementary functions of MDA5
and TLR3 in poly(I:C)-mediated activation of mouse NK cells. J. Exp Med
206(13) 2967-2976.
124. McDowell, M.A., M. Marovich, R. Lira, M. Braun and D. Sacks (2002) Leishmania
priming of human dendritic cells for CD40 ligand induced interleukin-12p70
secretion is strain and species dependent. Infection and Immunity 70:3994-4001.
125. McFarlane, E., C. Perez, M. Charmoy, C. Allenbach, K.C.Carter, J. Alexander and F.
Tacchini-Cottier (2008) Neutrophils contribute to development of a protective
immune response during onset of infection with Leishmania donovani. Infect
Immun 76: 532-541.
126. McHugh, C.P., P.C.Melby and S.G. LaFon (1994) Leishmaniasis in texas:
epidemiology and clinical aspects of human cases. Am J Trop Med Hyg 55(5):
547-555.
127. Melby, P. C., F. J. Andrade-Narvaez, B. J. Darnell, G. Valencia-Pacheco, V. V. Tryon
and A. Palomo-Cetina (1994) Increased expression of pro inflammatory cytokines
in chronic lesions of human cutaneous leishmaniasis. Infect Immun 62:837-842.
128. Miles, S. A., S.M. Conrad, R.G. Alves, S. M., Jeronimo, and D.M. Mosser (2005) A
role for IgG immune complexes during infection with the intracellular pathogen
Leishmania. J Exp Med 201: 747-754.
129. Mookerjee-Basu, J., A. Mookerjee, P. Sen, S. Bhaumik, P. Sen, S. Banerjee, K. Naskar,
S.K. Choudhuri, B. Saha, S. Raha and S. Roy (2006) Sodium antimony gluconate
induces generation of reactive oxygen species and nitric oxide via phosphoinositide
3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-
infected macrophages Antimicrob. Agents Chemother 50:1788-1797.
130. Moore, E., D. O. Flaherty, H. Heuvelmans, J. Seaman, H. Veeken, S. De Wit and R. N.
Davidson (2001) Comparison of generic and proprietary sodium stibogluconate for
XIII
the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ 79:
388-393.
131. Moore, I.D., T.W.Norton, and J. E. Williams (1993) Modelling environmental
heterogeneity in forested landscapes. J. Hydrol 150: 717-747.
132. Moore, K.W., A. Ogarra, R. de Waal Malefyt, P. Vieira, T.R. Mosmann (1993)
Interleukin-10. Annu Rev Immunol 11:165-190.
133. Moore, K.W., A. O’Garra, R. De Waal Malefyt, P. Vieira and T.R. Mosmann (1993)
Interleukin-10. Annu Rev Immunol 11165-11190.
134. Moreno, I., R. Molina, A. Toraño, E. Laurin, E. García and M. Domínguez (2007)
Comparative real-time kinetic analysis of human complement killing of
Leishmania infantum promastigotes derived from axenic culture or from
Phlebotomus perniciosus. Microbes Infect 9:1574-1580.
135. Moreno, J., and J. Alvar (2002) Canine leishmaniasis: epidemiological risk and the
experimental model. Trends Parasitol 18:399-405.
136. Mosmann, T.R., and R. L. Coffman (1989) TH1 and TH2 cells: different patterns of
lymphokine secretion lead to different functional properties. Annu Rev Immunol
7:145-173.
137. Murphy, M.L., U. Wille, E. N. Villegas, C.A. Hunter and J.P. Farrell (2001) IL-10
mediates susceptibility to Leishmania donovani infection. Eur J Immunol 31: 2848-
2856.
138. Murray, H.W., and C.F. Nathan (1999) Macrophage microbicidal mechanisms in vivo:
reactive nitrogen vs oxygen intermediates in the killing of intracellular visceral
Leishmania donovani. J Exp Med 189:741-746.
139. Murray, H.W., J.D. Berman, C.R. Davies and N.G. Saravia (2005) Advances in
leishmaniais. Lancet 366: 1561-1577.
140. Murugaiyan, G., A. Mittal, R. Lopez-Diego, L. M. Maier, D. E. Anderson and H. L.
Weiner (2009) IL-27 is a key regulator of IL-10 and IL-17 production by human
CD4+ T cells. J Immunol 183: 2435-2443.
141. Musa, A.M., S. Noazin, E.A. Khalil and F. Modabber (2010) Immunological
stimulation for the treatment of leishmaniasis: a modality worthy of serious
consideration. Trans R Soc Trop Med Hyg 104: 1-2.
142. Nelms, K., A.D. Keegan, J. Zamorano, J.J. Ryan and W.E. Paul (1999) The IL-4
receptor: Signaling Mechanisms and Biologic Functions. Annual Review of
Immunology 17: 701-738.
XIV
143. Neogy, A. B., A. Nandy, B. G. Dastidar and A. B. Chowdhury (1987). Antibody
kinetics in kala-azar in response to treatment. Ann Trop Med Parasitol 81:727-729.
144. Nylen, S., A. Khamesipour, A. Mohammadi, R. Jafari-Shakib, L. Eidsmo, S. Noazin, F.
Modabber and H. Akuffo (2006) Surrogate markers of immunity to Leishmania
major in leishmanin skin test negative individuals from an endemic area revisited.
Vaccine 24: 6944-6954.
145. Nylen, S., and D. Sacks (2007). Interleukin-10 and the pathogenesis of human visceral
leishmaniasis. Trends Immunol 28: 378-388.
146. Nylen, S., R. Maurya, L. Eidsmo, K. D. Manandhar, S. Sundar and D. Sacks (2007)
Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+ CD25
+
(Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med 204(4):
805-817.
147. Olivier, M., D.J. Gregory and G. Forget (2005) Subversion mechanisms by which
Leishmania parasites can escape the host immune response: a signaling point of
view. Clin Microbiol Rev 18: 293–305.
148. Palma, G.I., and N.G.Saravia (1997) In situ characterization of the human host response
to Leishmania panamensis. Am J Dermatopathol 19:585-590.
149. Pearson, R.D., and R.T. Steigbigel (1981) Phagocytosis and killing of the protozoan
Leishmania donovani by human polymorphonuclear leukocytes. J Immunol
27:1438-1443.
150. Perasons RD, De Queiroz Sousa A. (1995) Clinical spectrum of leishmaniasis. Clin
Infect Dis. 22: 1-13.
151. Peruhype-Magalhães, V., O.A. Martins-Filho, A. Prataz, L.A. Silva, A. Rabello, A.
Teixeira-Carvalho, R.M. Figueiredo, S. F. Guimarães-Carvalho, T.C.A.Ferrari and
R. Correa-Oliveira (2005) Immune response in human visceral leishmaniasis:
analysis of the correlation between innate immunity cytokine profile and disease
outcome. Scand J Immunol 62: 487-495.
152. Peters, N.C., J.G. Egen, N. Secundino, A. Debrabant, N. Kimblin, S. Kamhawi, P.
Lawyer, M.P. Fay, R.N.Germain and D. Sacks (2008) In vivo imaging reveals an
essential role for neutrophils in leishmaniasis transmitted by sandflies. Science
321:970-974.
153. Peters, W. (1981) The treatment of kala-azar. New approach to an old problem. Indian
Journal of Medical Research 73: 1-18.
XV
154. Pinelli, E., S. Y.van der Kaaij, R. Slappendel, C. Fragio, E. J. Ruitenberg, W. Bernadina
and V. P. Rutten (1999) Detection of canine cytokine gene expression by reverse
transcription polymerase chain reaction. Vet Immunol Immunopathol 69: 121-126.
155. Pita-Pereira, D., G.D. Souza, A. Zwetsch, C.R. Alves, C. Britto and E.F. Rangel (2009)
First report of Lutzomyia (Nyssomyia) neivai (Diptera: Psychodidae:
Phlebotominae) naturally infected by Leishmania (Viannia) braziliensis in a
periurban area of South Brazil using a multiplex polymerase chain reaction assay.
Am J Trop Med Hyg 80: 593-595.
156. Rais, S., A. Perianin, M. Lenoir, A. Sadak, D. Rivollet, M. Paul and M. Deniau (2000)
Sodium stibogluconate (Pentostam) potentiates oxidant production in murine
visceral leishmaniasis and in human blood. Antimicrob Agents Chemother 44:
2406-2410.
157. Ravindran, R., K. Anam, B. C. Bairagi, B. Saha, N. Pramanik, S. K. Guha, R. P.
Goswami, D. Banerjee and N. Ali (2004) Characterization of immunoglobulin G
and its subclass response to Indian kala-azar infection before and after
chemotherapy. Infect Immun 72: 863-870.
158. Redhu, N. S. A. Dey and S. Singh (2006) Use of Immunoglobulin G Avidity to
determine the course of disease in visceral and post-kala-azar dermal leishmaniasis
patients. Clin Vaccine Immunol 13 (8): 969-971.
159. Reiner, N. E., W. Ng, C. B. Wilson, W. R. McMaster and S. K. Burchett(1990)
Modulation of in vitro monocyte cytokine responses to Leishmania donovani.
Interferon-γ prevents parasite-induced inhibition of interleukin 1 production and
primes monocytes to respond to Leishmania by producing both tumor necrosis
factor-α and interleukin 1. Journal of Clinical Investigation 85(6) 1914-1924.
160. Reiner, S.L., and R. M. Locksley (1995) The regulation of immunity to Leishmania
major. Annu Rev Immunol 13:151–177.
161. Reithinger, R., J.C. Dujardin, H. Louzir, C Pirmez, B. Alexander and S. Brooker (2007)
Cutaneous leishmaniasis. Lancet Infect Dis 7: 581-596.
162. Ribeiro-de-Jesus, A., R.P. Almeida , H. Lessa, O. Bacellar and E.M. Carvalho (1998)
Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res
31:143.
163. Rijal, S., S. Koirala, P. Van der Stuyft M. Boelaert (2006) The economic burden of
visceral leishmaniasis for households in Nepal. Trans R Soc Trop Med Hyg 100,
838–841.
XVI
164. Rijal, S., S.Uranw, F. Chappuis, A. Picado, B. Khanal, I.S. Paudel, E.W. Andersen, F.
Meheus, B. Ostyn and M.L.Das (2010) Epidemiology of Leishmania donovani
infection in high transmission foci in Nepal. Trop Med Int Health 15:21-28.
165. Ritmeijer, K., H. Veeken, Y. Melaku, G. Leal, R. Amsalu, J. Seaman and R. N.
Davidson (2001) Ethiopian visceral leishmaniasis: generic and proprietary sodium
stibogluconate are equivalent; HIV co-infected patients have a poor outcome.
Transactions of the Royal Society of Tropical Medicine and Hygiene 95(6): 668-
672.
166. Ritter, U., F. Frischknecht and G. van Zandbergen, (2009) Are neutrophils important
host cells for Leishmania parasites? Trends Parasitol 25: 505-510.
167. Ritter, U., H. Moll, T. Laskay, E. Brocker, O.Velazco, I.Becker and R. Gillitzer (1996)
Differential expression of chemokines in patients with localized and diffuse
cutaneous American leishmaniasis. J Infect Dis 173: 699-709.
168. Roberts, L.J., E. Handman and S.J. Foote (2000) Science, medicine, and the future:
leishmaniasis. British Medical Journal 321(7264): 801-804.
169. Roger, K.A. G.K. Derkry, M.L. Mbow, R.D. Gillespie, C.L. Brodskyn and R.G. Titus
(2002) Type 1 and type 2 response to Leishmania major. FEMS Microbial Lett
209: 1-7.
170. Rousseau, D., S. Demartino, F. Anjuère, B. Ferrua, K. Fragaki, Y. Le Fichoux and J
Kubar(2001) Sustained parasite burden in spleen of Leishmania infantum
infected BALB/c mice is accompanied by expression of MCP-1 transcripts and
lack of protection against challenge. Eur Cytokine New 12:340-347.
171. Ruiz, H.J. and Becker (2007) CD8 cytotoxic T cells in cutaneous leishmaniasis. Parasite
Immunnolgy 29(12): 671-678.
172. Russell, D.G., S. Xu and P. Chakraborty (1992) Intracellular trafficking and the
parasitophorous vacuole of Leishmania Mexicana infected macrophages. J Cell Sci
103: 1193-1210.
173. Ryan, J. R., A. M. Smithyman, G. H. Rajasekariah, L. Hochberg, J. M. Stiteler and S.
K. Martin, (2002) Enzyme-linked immunosorbent assay based on soluble
promastigote antigen detects immunoglobulin M (IgM) and IgG antibodies in sera
from cases of visceral and cutaneous leishmaniasis. J Clin Microbiol 40:1037-
1043.
174. Sacks, D. L., and P. V. Perkins (1984) Identification of an infective stage of Leishmania
promastigotes. Science 223:1417-1419.
XVII
175. Safro, B.Y., N.O. Wilson, V.C. Bond an d J.K. Stiles (2011) Plasmodium berghei
ANKA infection increases Foxp3, IL-10 and IL-2 in CXCL-10 deficient
C57BL/6mice. Malaria Journal 10(69): 1-12.
176. Saitou, N. and M. Nei (1987) The neighbor- joining method: A new method for
reconstructing phylogenetic trees. Mol Bio Evol 4: 406-425.
177. Salhi, A.,V. Rodrigues, J.F. Santoro, H. Dessein, A.Romano, L. R. Castellano , M.
Sertorio, S. Rafati, C. Chevillard ,A. Prata, A. Alcaïs, L. Argiro and A. Dessein
(2008) Immunological and genetic evidence for a crucial role of IL-10 in cutaneous
lesions in humans infected with Leishmania braziliensis. J Immunol 180: 6139-6148.
178. Sambrook and J.D.W. Russel (2001) Molecular cloning: A laboratory manual. Cold
Spring Harbor Laboratory Press, New York.
179. Sane, S.A., N. Shakya and S. Gupta (2011) Immunomodulatory effect of picroliv on the
efficacy of paramomycin and miltefosine in combination in experimental visceral
leishmaniasis. Exp Parasitol 127: 376-381.
180. Schonian, G., A. Nasereddin, N. Dinse, C. Schweynoch, H.D. Schallig , W. Presber and
C.L. Jaffe (2003) PCR diagnosis and characterization of Leishmania in local and
imported clinical samples. Diagn Microbiol Infect Dis 47: 349-358.
181. Schonian, G., L. Schnur and M. Fahri (2001) Genetic heterogeneity in the species
Leishmania tropica revealed by different PCR-based methods. Trans R Soc Trop
Med Hyg 95:217-24.
182. Schwartz, E., H. Cristoph and B. Johannes (2006) New world cutaneous leishmaniasis
in travelers. The Lancet Infectious Disease 6(6): 342-349.
183. Scott, P. and R.M. Locksley (1991) Helper T-cell subsets in mouse leishmaniasis:
induction, expansion and effector function. J. Exp. Med., 168:1675-1684.
184. Seaman J, Mercer AF, Sondrop E. (1996) The epidemic of VL in Western Upper Nile,
sourthern Sudan: course and impact from 1984 to 1994. Int J Epidemiol. 25(4):
862-871.
185. Seifert, K. (2011) Structures, targets and recent approaches in anti-leishmanial drug
discovery and development. Open Med Chem J 5: 31–39.
186. Sen, E., S. Chattopadhyay, S. Bandopadhyay, T. De and S. Roy (2001) Macrophage
heterogeneity, antigen presentation, and membrane fluidity: implications in
visceral leishmaniasis. Scan J Immunol 53:111-120.
187. Shakya, N., S.A. Sane, P. Vishwakarma and S, Gupta (2012) Enhancement
intherapeutic efficacy of miltefosine in combination with synthetic bacterial
XVIII
lipopeptide, Pam3Cys against experimental visceral leishmaniasis. Exp Parasitol
131: 377–382.
188. Sharma ,M.C., A. K. Gupta, V. N. Das, N. Verma, N. Kumar, R. Saran and S. K. Kar
(2000). Leishmania donovani in blood smears of asymptomatic persons. Acta Trop.
76(2):195-196.
189. Sharma, N.L., V.K. Mahajan, A. Kanga, A. Sood, V.M. Katoch, I. Mauricio,
U.C.Parwan, V.K.Sharma and R.C. Sharma (2005) Localized cutaneous
leishmaniasis due to leishmania donovani and leishmania tropica: preliminary
findings of the study of 161 new cases from a new endemic focus in himachal
pradesh, India. Am. J. Trop. Med. Hyg 72(6) : 819-824.
190. Shiddo, S. A., G. Huldt, L.A. Nilsson, O. Ouchterlony and R. Thorstensson (1996).
Visceral leishmaniasis in Somalia. Significance of IgG subclasses and of IgE
response. Immunol Lett 50: 87-93.
191. Singh, A.K., B. Papadopoulou and M. Ouellette (2001) Gene amplification in
amphotericin B-resistant L-tarentolae. Exp Parasitol 99: 141-147.
192. Singh, R., R.K. Das and S. K. Sharma (2001) Resistance of sandflies to DDT in Kala-
azar endemic districts of Bihar. India. Bull World Health Organ 79: 793.
193. Singh, S. P., D. C. Reddy, M. Rai and S. Sundar (2006) Serious underreporting of
visceral leishmaniasis through passive case reporting in Bihar, India. Trop Med Int
Health 11: 899-905.
194. Smelt, S.C., C.R. Engwerda, M. McCrossen and P.M. Kaye (1997) Destruc- tion of
follicular dendritic cells during chronic visceral leishmaniasis. J Immunol 158:
3813-3821.
195. Smelt, S.C., S. E. Cotterell, C. R. Engw-erda and P.M. Kaye (2000) B cell-deficient
mice are highly resistant to Leishmania donovani infection, but develop neutrophils
mediated tissue pathology. J Immunol 164:3681-3688.
196. Sundar S, D. K. More, M. K. Singh, V. P. Singh, S. Sharma, A. Makharia, P. C. K.
Kumar, and H. W. Murray (2000) Failure of pentavalent antimony in visceral
leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect
Dis 31: 1104-1107.
197. Sundar, S., and M. Rai (2002) Laboratory diagnosis of visceral leishmaniasis.Clin Diag
Lab Immunol 9: 951-958.
XIX
198. Sundar, S., B. B. Thakur, A.K. Tandon, N. R. Agrawal, C. P. Mishra, T. M. Mahapatra,
and V. P. Singh. (1994) Clinico-epidemiological study of drug resistance in Indian
kala-azar. British Medical Journal 308: 307-307.
199. Sundar, S., G. Agrawal, M. Rai, M. K. Makharia, H. W. Murray and D. NJ Lockwood
(2001) Treatment of Indian visceral leishmaniasis with single or daily infusions of
low dose liposomal amphotericin B: randomised trial. BMJ 323:419-22.
200. Sundar, S., M., Rai, J. Chakravarty, D. Agarwal, N, Agrawal, M. Vaillant, P. Olliaro
and H. W. Murray (2008) New treatment approach in Indian visceral leishmaniasis:
single-dose liposomal amphotericin B followed by short-course oral miltefosine.
Clin Infect Dis 47(8): 1000-1006.
201. Sundar, S., T.K. Jha, C.P. Thakur, J. Engel, H. Sindermann, C. Fischer, K. Junge, A.
Bryceson and J. Berman (2002) Oral Miltefosine for Indian Visceral
Leishmaniasis. N Engl J Med 347: 1739-1746.
202. Sunder, S., J. Chakavarty, V.K. Rai, N. Agrawal, S.P. Singh, V. Chauhan, H.W.
Murray(2007) Amphotericin B treatment for Indian visceral leishmaniasis:
response to 15 daily versus alternate- day infusions. Clin Infect Dis 45: 556-561.
203. Tamura, K., D. Peterson, N. Peterson, G. Stecher, M. Nei and S. Kumar (2011)
MEGA5: Molecular Evolutionary Genetics Analysis using Maximum Likelihood,
Evolutionary Distance, and Maximum Parsimony Methods. Mol Bio Evol.
204. Tamura, K., M. Nei and S. Kumar (2004) Prospects for inferring very large phylogenies
by using the neighbor-joining method. PNAS USA 101: 11030-11035.
205. Tangteerawatana, P., S. Pichyangkul, M. Hayano, T. Kalambaheti, S. Looareesuwan M.
T. Blomberg and S. Khusmith (2007) Relative levels of IL-4 and IFN-γ in
complicated malaria: associationwith IL-4 polymorphism and peripheral
parasitemia. Acta Tropica 101: 258-265.
206. Tejle, K., M. Lindroth, K. E.Magnusson and B. Rasmusson (2008) Wild type
Leishmania donovani promastigotes block maturation, increase integrin expression
and inhibit detachment of human monocytes derived dendritic cells the influence of
phosphor glycans. FEMS Microbiol Lett 279:92-102.
207. Thakur, C. P., M. Kumar and A.K. Pandey (1991) Comparison of regimens of treatment
of antimony-resistant kala-azar patients: a randomized study. American Journal of
Tropical Medicine and Hygiene 45: 435-441.
208. Thakur, C.P., G.P. Sinha, A.K. Pandey, N. Kumar, P. Kumar, S. M. Hassan, S. Narain
and R. K. Roy (1998) Do the diminishing efficacy and increasing toxicity of
XX
sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India,
justify its continued use as a first-line drug? An observational study of 80 cases.
Ann Trop Med Parasitol 92(5):561-569.
209. Thakur, C.P., M. Kumar, S.K. Singh, D. Sharma, U. S. Prasad, R. S. Singh, P. S.
Dhawan and V. Achari (1984) Comparison of regimens of treatment with sodium
stibogluconate in kala-azar. British Medical Journal 288(6421): 895-897.
210. Thornton, A.M., C.A. Piccirillo and E.M. Shevach (2004) Activation requirements for
the induction of CD4+CD25
+ T cell suppressor function. Eur J Immunol 34:366-
376.
211. Tiuman, T.S., A.O. Santos, T. Ueda-Nakamura, B.P. Filho, C.V. Nakamura (2011)
Recent advances in leishmaniasis treatment. Int J Infect Dis 15: 525–532.
212. Tumang, M.C.T., C. Keogh and L.L. Moldawer (1994) Role and effect of TNF-α in
experimental visceral leishmaniasis. J Immunol 153: 768-775.
213. Tuon, F. F., V. S. Amato, M. E. Graf, A. M. Siqueira, A. C. Nicodemo, and V. Amato
Neto, (2008) Treatment of New World cutaneous leishmaniasis a systematic
review with a meta-analysis. Int J Dermatol 47:109-24.
214. Ulrich, M., V. Rodriguez, M. Centeno and J. Convit (1995) Differing antibody IgG
isotypes in the polar forms of leprosy and cutaneous leishmaniasis characterized by
antigen-specific T cell anergy. Clin Exp Immunol 100: 54-58.
215. Unanue, E.R., and P.M. Allen (1987) The basis for the immunoregulatory role of
macrophages and other accessory cells. Science 236:551-557.
216. Van Thiel, P., T. Leenstra, H. de Vries, A. van der Sluis, T. van Gool, A. Krull, M. van
Vugt, P. de Vries, J. Zeegelaar, A. Bart, W. van der Meide, H .Schallig, W. Faber
and P. Kager (2010) Cutaneous leishmaniasis (Leishmania major infection) in
Dutch troops deployed in northern Afghanistan: epidemiology, clinical aspects and
treatment. Am J Trop Med Hyg 83: 1295-1300.
217. Vanaerschot, M., I. Maes, M. Ouakad, V. Adaui, L. Maes, S. De Doncker, S. Rijal, F.
Chappuis, J.C. Dujardin and S. Decuypere (2010) Linking in vitro and in vivo
survival of clinical Leishmania donovani strains. PLoS ONE 5 (8): e12211.
218. Vanaerschot, M., S. De Doncker, S. Rijal, L. Maes, J.C. Dujardin and S. Decuypere
(2011) Antimonial resistance in Leishmania donovani is associated with increased
in vivo parasite burden. PLoS One 6: e23120. doi: 10.1371/journal.pone.0023120.
219. WHO, (2010) Control of the leishmaniases. World Health Organ. Tech Rep Ser XII–
XIII: 1–186
XXI
220. WHO, (2011) Leishmaniasis: Magnitude of the Problem. World Health Organization.
221. Wilson, A.J., D.W. Coltman, J.M.Pemberton, A.D.J.Overall, K.A. Byrne and L.E.B.
Kruuk (2005) Maternal genetic effects set the potential for evolu- tion in a free-
living vertebrate population. Journal of Evolutionary Biology 18: 405-414.
222. World Health Organization (1990) Control of leishmaniasis. Technical report series -
793 Printed in Switzerland.
223. World Health Organization (1998) Leishmania and HIV in gridlock.
WHO/CTD/LEISH/98.1 and UNAIDS/98.23.
224. Wozencraft, A.O., and J.M. Blackwell (1987) Increased infectivity of stationary-phase
promastigotes of Leishmania donovani: Correlation with enhanced C3 binding
capacity and CR3-mediated attachment to host macrophages. Immunology 60: 559-
563.
225. Wyllie, S., M.L. Cunningham and A.H. Fairlamb (2004) Dual action of antimonial
drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J
Biol Chem 279: 39925–39932.
226. Young, D.G., and P.G. Lawyer (1987) New World vectors of the leishmaniases. In
Current Topics in Vector Research 4:29-71.
227. Zijlstra, E.E., A.M. Musa, E.A.G. Khalil, I.M. El Hassan and A.M. El-Hassan (2003)
Post-Kala-azar dermal leishmaniasis. Lancet 3:87-98.
228. Zlotnik, A., and K.W. Moore (1991) Interleukin 10. Cytokine 3:366-371.
229. Zwingenberger, K., G. Harms, C. Pedrosa, S. Omena, B. Sandkamp and S. K. Neifer
(1990) Determinants of the immune response in visceral leishmaniasis: evidence
for predominance of endogenous interleukin 4 over interferon- production. Clin.
Immunol. Immunopathol 57: 242-249.